Chatbots now steer patient choice, surfacing providers with rich, accurate site data.
Pharma companies back rapid reviews to speed patient access, while opponents are concerned about transparency lapses and safety trade-offs.
HealthlineAI offers pharma marketers a new way to reach high-intent patients. But it must contend with consumers going to general-purpose chatbots for health info.
Edelman study finds falling confidence in doctors, CEOs, and government as Americans consult a wider mix of health information sources.
Just 7% of US adults use AI chatbots extremely often or often for health information, while 59% never use them at all, ranking chatbots last among seven major health information sources, according to an October 2025 Pew Research Center survey.
Physicians integrate both general-purpose and clinical AI into daily workflows, increasing pressure on pharma brands to tailor drug content for the distinct requirements and outputs of each AI ecosystem.
Among ages 12 to 21, AI use for mental health rose 40% year over year, bringing chatbots further into their mainstream coping habits.
Most Americans call them addictive and blame them for obesity and diabetes, priming tougher policies and regulations.
Reduced employer coverage of weight loss drugs could push patients to cash-pay options or off treatment, increasing pressure on pharma companies to lower prices.
Doctors review AI advice that patients bring to appointments, but still have concerns about its accuracy. Healthcare marketers have room to help guide responsible genAI use.
They’re forging multibillion-dollar licensing and collaboration agreements to bolster drug pipelines as the US’ lead in drug development slips.
LinkedIn posts from digital health founders generate more engagement and AI citations than brand profiles, increasing visibility and discoverability beyond company pages.
US obesity is edging down as GLP-1 prescriptions climb, but high prices and low coverage may limit impact.
As consumers source wellness peptides via online retailers, social apps, and overseas sellers, regulated drugs and gray-market products may blur, elevating safety risks.
One-third of CFOs now rank health benefits among their top three operating concerns, and it’s driving cuts to coverage, hiring, and investment.
The US spends far more on prescription medicines than other developed nations and policy efforts are unlikely to narrow the gap.
Amazon should resist trying to disrupt US healthcare and instead focus on delivering a consumer-friendly care experience.
Healthcare membership buyers tend to skew younger, but a new GoodRx offering could tap a broader market of consumers losing coverage while still needing routine care.
Ad watchdog sides with pharma over misleading GLP-1 microdose telehealth marketing—but this scrutiny won't impact sales thanks to high consumer demand.
Oura's smart ring adds blood pressure signals, health records, and clinician chat—further blurring the line between wellness tools and healthcare tools.